Hence, adiponectin is an interesting endogenous therapeutic candidate for the prevention of metabolic-associated neurodegenerative diseases such as AD [14–16, 23], and future studies should investigate mimetics of adiponectin that will also act as adiponectin receptor agonists because the conversion of full-length adiponectin into an effective drug is limited due to its size. This evidence concerns the gene ADIPOQ and Alzheimer disease.